Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-Directed Post-Hepatectomy Chemotherapy for Colorectal Liver Metastases
NCT05062317Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, capecitabine in colorectal liver metastases (CRLM), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2022; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT05062317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062317.